戻る
Shanghai Henlius Biotech, Inc. (02696.HK)価格
02696.HK 株価推移チャート
HENLIUS (02696.HK)
Shanghai Henlius Biotech, Inc.
HK$68.25
1.26%
$0.84
休場: Jan 19, 12:00:00 HKT
データなしEarnings FAQ
02696.HKの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
Shanghai Henlius Biotech, Inc. 02696.HKの前四半期の収益はどうでしたか？
Shanghai Henlius Biotech, Inc.の収益見積もりはいくらですか？
Shanghai Henlius Biotech, Inc.の収益品質スコアはどれくらいですか？
Shanghai Henlius Biotech, Inc.はいつ収益を報告しますか？
Shanghai Henlius Biotech, Inc.の予想収益はいくらですか？
Shanghai Henlius Biotech, Inc.は収益予想を上回りましたか？
主要データ
前終値
$67.4
始値
$67.4
当日レンジ
$66.55 - $69.9
52週レンジ
$15.2 - $92
取引高
64.7K
平均取引高
1.1M
1株当たり利益(TTM)
1.69
配当利回り
--
時価総額
$11.1B
HENLIUSとは何ですか？
Shanghai Henlius Biotech, Inc. engages in the production and sale of monoclonal antibody (mAb) drugs and the provision of related consultation and technical services, and the transfer of its own technology. The company is headquartered in Shanghai, Shanghai and currently employs 3,537 full-time employees. The company went IPO on 2019-09-25. The Company’s main products include HANQUYOU (trastuzumab for injection), HANNAIJIA (neratinib maleate), HANSIZHUANG (serplulimab injection), HANLIKANG (rituximab injection), HANDAYUAN (adalimumab injection), HANBEITAI (bevacizumab injection) and others. The Company’s products are mainly used in the treatment of adjuvant breast cancer, metastatic breast cancer, metastatic gastric cancer, metastatic non-squamous non-small cell lung cancer, polyarticular juvenile idiopathic arthritis and others. The firm mainly operates its businesses in the domestic and overseas markets.